Investing.com — InvestingPro会员锁定我们每月更新的股票精选名单，每月不到8美元——作为我们限时早鸟促销的一部分——正在抓住今年最大的几次市场突破机会。
Investing.com — InvestingPro members who locked in our monthly-updated list of stock picks for less than $8 a month—as part of our limited-time-only Early Bird Sale—are capitalizing on some of the year’s biggest market breakouts.
11月在科技、能源和医疗保健领域做出了及时的判断——仅过了几天，就带来了十几只两位数涨幅的赢家。表现突出的包括康美德（NYSE:CNMD）上涨+21.16%，利瓦诺瓦（NASDAQGS:LIVN）上涨+19.27%，以及加拿大太阳能（NASDAQGS:CSIQ）上涨+16.41%，仅11月一个月。
November has seen timely calls across tech, energy, and healthcare — delivering a dozen double-digit winners just days into the month. Standout performers include CONMED (NYSE:CNMD) up +21.16%, LivaNova PLC (NASDAQGS:LIVN) up +19.27%, and Canadian Solar Inc (NASDAQGS:CSIQ) up +16.41% in November alone.
这些回报加上一长串持续推进的精选股票，这些股票在过去几个月里持续上涨。就在今天早上，随着美国市场重新开放，一家高信心的生物科技公司在盘前交易中飙升+10.38%（截至撰稿时），达到11.80美元。此次走势发生在该公司股价在第三季度财报公布前积累动力之际，财报将于今晚收盘后公布，此前该公司第二季度业绩出色，带来了高达533%的盈利惊喜。
These returns add to a long list of ongoing picks extending gains in recent months. Just this morning, as US markets reopen, one high-conviction biotech player is surging +10.38% in pre-market trading (at the time of writing) to $11.80. The move comes as shares build momentum ahead of the company’s Q3 earnings report scheduled after the bell tonight, following a blowout second quarter that produced a massive 533% earnings surprise.
现在，您可以以不到8美元一个月的价格——迄今2026年的最低价格——获得同样的模型，该模型做出了那些预测，还有其他几只高潜力股票。限时期间，Investing.com的早鸟促销最高提供55%的折扣，让您获得同样投资级的研究，这些研究让高级会员全年都能抢先把握这些机会。
Right now, you can access the same model that delivered those call, with several other high-potential names for less than $8 a month — the lowest price of 2026 so far! For a limited time, Investing.com’s Early Bird Sale is giving up to 55% off access to the same investor-grade research that has kept premium members positioned ahead of these calls all year long.
这些胜利并非孤例。以下是会员目前持有的其他一些巨额收益，自其股票首次被选中以来：Everforth（NYSE:EFOR）：自被选中以来上涨+110.59% Delek US Holdings（NYSE:DK）：自被选中以来上涨+74.53% Consensus Cloud Solutions（NASDAQGS:CCSI）：自被选中以来上涨+74.06% Nucor（NYSE:NUE）：自被选中以来上涨+68.67% Amneal Pharmaceuticals（NASDAQGS:AMRX）：自被选中以来上涨+54.65%还有更多！
And these wins are not alone. Here are some of the other massive gains members are currently sitting on since their stocks were first selected: Everforth (NYSE:EFOR): +110.59% since picked Delek US Holdings (NYSE:DK): +74.53% since picked Consensus Cloud Solutions (NASDAQGS:CCSI): +74.06% since picked Nucor (NYSE:NUE): +68.67% since picked Amneal Pharmaceuticals (NASDAQGS:AMRX): +54.65% since picked Among many more!
想看完整名单吗？InvestingPro会员可以在此处查看11月完整的人工智能驱动股票精选名单。还不是会员？那么现在就是您获取完整名单的机会：哪只生物科技明星股票盘前上涨10%？
Want to see the full list? InvestingPro members can access November’s complete set of AI-powered stock picks HERE. Still not a member? Then here’s your chance to get the full list NOW: Which biotech standout is up 10% premarket?
该股票为普马生物技术公司（纳斯达克代码：PBYI）。这家生物制药公司在第三季度财报发布前股价上涨，此前其第二季度业绩大幅超越市场共识预期，每股摊薄收益为0.16美元，远高于预期的0.03美元（超额533%以上），营收达5650万美元。该公司主打商业疗法NERLYNX实现了美国需求连续两年增长——这是该药物历史上前所未有的里程碑。加上公司资产负债表现已完全无债务，且全年业绩指引上调，普马正吸引激进的盘前资金积累筹码。
That stock is Puma Biotechnology Inc. (NASDAQGS:PBYI). The biopharmaceutical firm is rallying ahead of its third-quarter financial release after previously crushing Q2 consensus estimates with diluted EPS of $0.16 against expectations of just $0.03 (a 533%+ beat) on revenue of $56.5 million. The company’s lead commercial therapy, NERLYNX, achieved two consecutive years of rising U.S. demand—an unprecedented milestone in the drug’s history. Combined with a balance sheet that is now completely debt-free and upwardly revised full-year guidance, Puma is drawing aggressive premarket accumulation.
ProPicks AI正是为此而生——运用机构级财务研究和机器学习模型，覆盖全球6万余只股票，在更广泛的市场察觉之前，发掘基本面与增长前景指向超额波动的公司。
ProPicks AI was built for exactly this — applying investor-grade financial research and machine-learning models to more than 60,000 stocks worldwide to find the companies where fundamentals and growth outlook are pointing to outsized moves before the broader market catches on.
我们的模型在普马生物技术股价飙升前识别出的信号 我们的机器学习引擎基于价格上涨动能增强、盈利能力加速改善以及估值吸引力窗口开启，将普马生物技术选为高确信度交易机会。以下是机器学习引擎在股价上涨前捕捉到的关键因素：盈利增长与合理价值上行空间：该股过去一年上涨约80%（在更长的回溯窗口中涨幅达116%），过去六个月上涨约60%。
What our models identified in Puma Biotechnology before the surge Our machine learning engine selected Puma Biotechnology as a high-conviction setup driven by rising price momentum, accelerating profitability, and an attractive valuation window. Here is what the ML engine saw before the move: Profitable Growth & Fair Value Upside: The stock has surged ~80% over the past year (up 116% across broader trailing windows) and gained ~60% over the last six months.
尽管已有这波涨幅，股价仍远低于InvestingPro的合理价值估计12.55美元（较前收盘价有逾17%上行空间），这得益于强劲的自由现金流收益率和健康的盈利能力概况。
Despite that rally, shares continued to trade well below InvestingPro’s Fair Value estimate of $12.55 (over 17% upside from previous close), backed by strong free cash flow yield and a healthy profitability profile.
第二季度大幅超预期及上调指引：普马在2026年第二季度果断扭亏为盈，实现营收5650万美元和GAAP净利润820万美元（每股收益0.16美元，预期0.03美元）。管理层以运营层面的超额表现为支撑，将2026全年NERLYNX产品营收指引上调至2.05亿至2.09亿美元，净利润指引上调至1700万至2000万美元。
Standout Q2 Beat & Raised Guidance: Puma decisively returned to profitability in Q2 2026 after a Q1 loss, generating $56.5 million in revenue and $8.2 million in GAAP net profit ($0.16 per share vs. $0.03 expected). Management backed up the operational beat by lifting full-year 2026 NERLYNX product revenue guidance to $205–$209 million and net income to $17–$20 million.
无债务资产负债表与需求上升：NERLYNX的商业化执行实现了27.6%的季度环比收入增长，同时美国需求连续两年增长。与此同时，普马生物在偿还最后一笔Athyrium贷款后消除了未偿债务，以无债务状态结束本季度，持有9390万美元现金，可支持正在进行的II期临床管线开发（包括阿利西替尼），且无稀释性资本压力。
Debt-Free Balance Sheet & Rising Demand: Commercial execution on NERLYNX delivered sequential revenue expansion of 27.6% alongside two consecutive years of U.S. demand gains. Concurrently, Puma eliminated its outstanding obligations following its final Athyrium loan repayment, ending the quarter debt-free with $93.9 million in cash to support ongoing Phase II clinical pipeline development (including alisertib) without dilutive capital pressure.
我们的AI模型为每一只选入或剔除的股票提供相同的详细理由，因此会员能确切了解当时数据显示的情况。
Our AI models provide the same detailed rationale for every stock they select or remove, so members know exactly what the data showed at the time.
想查看完整名单？InvestingPro会员可在此获取11月完整的AI选股名单（及其理由）——现作为早鸟特惠一部分，最高可享55%折扣。凭借专业级金融智能支持，我们每月更新的科技股精选自2023年11月正式推出以来，累计回报高达+169.88%。这比基准标普500指数高出惊人的+88.37%。
Want to see the full list? InvestingPro members can access November’s complete set of AI-powered stock picks (and their rationales) HERE - Now available at up to 55% off as part of our Early Bird Sale Backed by professional-grade financial intelligence, our monthly-updated list of tech picks has absolutely crushed the broader market, posting a +169.88% return since launching in November 2023. That is an incredible +88.37% outperformance over the benchmark S&P 500.
*这些是自2023年11月AI模型正式上线以来记录的真实数据。
*These are real-world numbers, recorded since the official launch of our AI models in November 2023.
这就是避开高估标的、在大众反应前发掘全新价值的力量。10月的工作已完成，下一个周期已然开启。
That is the power of moving out of overextended names and finding fresh value before the crowd does. The work for October is done, and the next cycle has already begun.
11月全新AI精选股票名单现已上线。使用ProPicks，订阅者不仅获得代码列表，更能获取我们所有策略中每一次增减仓背后的精确理由，帮助投资者在广泛市场反应前做出基于数据的明智决策。
A New List of AI-Picked Stocks for November IS NOW LIVE With ProPicks, subscribers don’t just receive a list of tickers. They gain access to the precise rationale behind every single addition and removal across our strategies, helping investors make informed, data-backed decisions before the broader market reacts.
不要错过查看11月完整精选名单的机会，精准掌握聪明资金下一步的动向。
Do not miss the opportunity to review the full list of November picks and see exactly where the smart money is moving next.
作为早鸟特惠一部分，您现在订阅InvestingPro最高可享55%折扣！已是会员？点此直接跳转至11月完整精选名单。
As part of our Early Bird Sale, you can secure an InvestingPro subscription for up to 55% off! Already a member? Jump straight to the FULL list of November picks HERE.
还不是会员？现在正是获取完整名单的机会 AI选股器如何运作 每月初，我们的专有AI系统利用历史数据、估值信号和前瞻性增长指标的复杂组合，评估数千只全球股票。
Not yet a member? Here’s your opportunity to access the full list now How the AI Stock Picker Works At the beginning of each month, our proprietary AI system evaluates thousands of global equities using a complex blend of historical data, valuation signals, and forward-looking growth metrics.
通过处理跨越15年以上、涵盖150多个量化模型的财务数据，该引擎根据预期的中期上涨潜力，为每项策略识别出最多20只高信心股票。
By processing more than 15 years of financial data across more than 150 quantitative models, the engine identifies up to 20 high-conviction stocks per strategy based on their projected medium-term upside potential.
每月，这些策略都会经历严格的再平衡过程。新机会被加入，强势表现者被保留，不再符合标准的股票被剔除。
Every month, these strategies undergo a strict rebalancing process. New opportunities are added, strong performers are retained, and stocks that no longer meet the criteria are removed.
为持续追踪表现，每项策略对所有入选股票采用等权重配置。投资者可自由调整自身配置，但这一结构为评估整体模型表现提供了透明的基准。目标是随着市场条件演变，系统性地将资金重新配置至最强机会。
To consistently track performance, each strategy utilizes equal weighting across all selected stocks. While investors are free to adjust their own allocations, this structure provides a transparent benchmark for evaluating overall model performance. The objective is to systematically reposition capital toward the strongest opportunities as market conditions evolve.
免责声明：文章中提及的订阅价格在发布时准确。我们定期为会员测试不同优惠，具体可能因地区而异。
Disclaimer: Subscription prices mentioned in articles are accurate at the time of publication. We regularly test different offers for our members, which may vary by region.